Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Kyowa Kirin (TSE:4151) has caught investors’ attention recently, with shares moving in ways that may prompt some to question whether this is a meaningful signal for the stock’s outlook. There is no ...

Amgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational ...

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Thousand Oaks, California Wednesday, September 10, 2025, 10:00 Hrs [IST] ...

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab ...

Amgen (AMGN) and Kyowa Kirin announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an ...

Kura Oncology, Inc. ( NASDAQ: KURA) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...

Results from the Phase III ASCEND trial (NCT05882877) showed rocatinlimab maintained long-term efficacy with a favorable ...

Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based ...